Indus Biotech is a drug discovery company involved in identifying a new generation of safe molecules to treat autoimmune, oncology, central nervous system, infectious and lifestyle diseases.
Since the drug discovery business is expensive and time-consuming, Indus Biotech has evolved a unique two-pronged business model:
The company uses well designed discovery processes with "statistically significant evidence of benefit" from randomized clinical trials (RCTs). This innovative methodology significantly reduces time to market and drives down costs to a fraction of what it would be by preventing expensive failures.
Starting with chosen food chain raw materials, the company uses a proprietary partitioning technology to separate NCE molecules from food chain raw materials with a focus on isolating molecules with FcyRIIB binding and c-Type Lectin Binding. Additionally, a platform technology for extraction, isolation and purification creates several poly-molecular formulations with physiological activity that can be positioned for marketing.
While Indus Biotech will focus on NCE and botanical drugs for value generation over the long term, it is currently using exercise physiology and herbal medicine to generate revenues over the short term.
The company has a discovery pipeline of seven NCEs at the moment, with strong activity in 13 therapeutic areas. These molecules are duly elucidated and patents granted (35) / applied for (25) under PCT/USPTO. The company has obtained IND approval from US Food & Drug Administration (FDA) for its drug candidate for HIV (No: IND 102862).
All the drug candidates are compliant with the US FDA's botanical drug guidelines. As the company develops purified single molecules derived from plants, these drug candidates are potential NCEs selectively pursued for co-development partnerships with global pharma majors.
For more information: www.indusbiotech.com
Global investors are betting big on India�s long-term growth story.India istoday one of the most attractive emerging markets across Asia with a billion plus captive consumers. Kotak Private Equity is well positioned to develop compelling local investing themes.
Through macro research, in-house analytics and frequent industry interactions, we identify industry and socio-economic trends, local consumption patterns and need-gap opportunities on an ongoing basis. With a cumulative experience of successfully investing in over 100 growth companies, we regularly refine our investment focus based on emerging trends, sectors and investment opportunities.
Our team�s past investments include backing some of India�s most successful entrepreneurs across many of the sectors mentioned above.
At Kotak Private Equity, we believe in partnering with companies, not operating them. We partner to accelerate growth through need based strategic value-addition in a variety of ways. In addition to capital, we bring our expertise, experience and commitment to create a shared vision and value.
We believe that we can never substitute an entrepreneur�s energy, passion and drive. Hence, at Kotak Private Equity, we like to complement these skills with strategic growth advice, skill enhancement and operational efficiency to disproportionally deliver on his business plan.
At Kotak Private Equity, we follow an investment process that has been developed through years of investment experience. The investment process captures the sensitivities and challenges of growing businesses in an Indian business environment as well our past experiences in dealing with Indian entrepreneurs.
Since its inception,Kotak Private Equity has been the preferred investment partner with local management teams on account of its transparent and rigorous investment process, significant value creation and strategic and timely exit.
We design bespoke investment structures for each of ourportfolio companies based on theirindividual growth requirements. We believe in patient investing through structured instrumentsthat help build partnerships with management teamsanddeliver on mutually aligned goals and incentives.